 - Reported responses in multiple solid tumor types during ASCO with updates at upcoming congresses in Q4 -- Continued progress toward launch of ADP-A2M4 for sarcoma in the US in 2022 with ongoing enrollment of patients in SPEARHEAD-1 - - Granted access to PRIority MEdicines PRIME regulatory support by the European Medicines Agency for ADP-A2M4 for the treatment of synovial sarcoma -- Completed public offering with net proceeds of approximately 244m; guidance confirmed: funded into 2022 -- Conference call to be held today at 8:00 a.m. EDT 1:00 p.m. BST -PHILADELPHIA and OXFORDSHIRE, United Kingdom, Aug. 06, 2020 GLOBE NEWSWIRE -- Adaptimmune Therapeutics plc Nasdaq: ADAP, a leader in cell therapy to treat cancer, today reported financial results and provided a business update for the second quarter ended June 30, 2020.We reported responses in multiple solid tumor types during the second quarter of 2020 demonstrating the potential of SPEAR Tcells to deliver benefit to people with cancer. We also raised capital, placing us in a solid financial position to continue executing on our strategic plans, said Adrian Rawcliffe, Adaptimmunes Chief Executive Officer. Despite the impact of the COVID-19 pandemic on the biotech industry, we made good progress in our preparations toward launching our first product in the US in 2022 for patients with sarcoma, whilst initiating and planning new Phase 2 clinical trials. However, as we enter the second half of the year, we expect COVID-19 to continue to have an impact and are monitoring this evolving situation closely.PLANNED MILESTONES 2H 2020 Update on ADP-A2AFP Phase 1 trial at the International Liver Congress to be held virtually from August 27 to 29 - An oral presentation entitled Data from the third dose cohort of an ongoing study with ADPA2AFP SPEAR T-cells will be presented by Dr. Bruno Sangro of Clinica Universidad de Navarra - A poster summarizing data from the first two cohorts of the ADP-A2AFP Phase 1 trial will be presented by Dr. Tim Meyer of University College London Updates on dose escalation cohorts from the SURPASS trial at a medical conference Durability and translational data from patients with synovial sarcoma from the ADP-A2M4 Phase 1 trial at a medical conference Investor Day to be held on November 20, 2020 CLINICAL UPDATES With timeline continuing to support 2022 launch in the US, enrollment in the Phase 2 SPEARHEAD-1 trial of ADP-A2M4, for patients with synovial sarcoma or myxoid round cell liposarcoma MRCLS, continues to progress The evolving COVID-19 pandemic continues to have an impact on clinical trials varying site-by-site and among countries Phase 1 trials ADP-A2AFP, radiation sub-study, and SURPASS continue and patients are being enrolled and treated First site has been initiated and has started screening patients for the SPEARHEAD-2 Phase 2 clinical trial, combining ADPA2M4 with pembrolizumab for people with head and neck cancer Protocol design for the Phase 2 trial with ADP-A2M4CD8 in gastroesophageal cancers has commenced and sites are being identified. The Company plans to initiate this trial in the first half of 2021PROGRESS TOWARD GOAL OF LAUNCHING ADP-A2M4 IN SARCOMA IN THE US IN 2022 Granted access to PRIME regulatory support by the EMA further confirming the potential of ADPA2M4 to treat people with advanced sarcoma, along with the previously granted Orphan Drug Designation ODD in Europe, as well as the FDAs ODD and Regenerative Medicine Advanced Therapy designationMANUFACTURING AND SUPPLY The Company has focused on manufacturing SPEAR T-cells for patients in the SPEARHEAD-1 trial and increasing capacity to provide for all ongoing and planned trials Scaling up personnel, manufacturing processes and IT systems, and optimizing space in our Navy Yard facility in preparation for commercial launch in sarcoma Following receipt of a Certificate of GMP Compliance from the MHRA for its vector manufacturing operations in July, the Company began using lentiviral vector produced in-house at its dedicated manufacturing space within the Cell and Gene Therapy Catapult Manufacturing Centre at Stevenage, UK for select clinical trials FUNDING Underwritten public offering closed on June 4, 2020 generating net proceeds of approximately 244 millionFinancial Results for the three and six month periods ended June 30, 2020 Cash liquidity position: As of June 30, 2020, Adaptimmune had cash and cash equivalents of 122.4 million and Total Liquidity1 of 419.0 million. Revenue: Revenue for the three and six months ended June 30, 2020 was 0.5 million and 1.3 million, respectively, compared to 0.2 million for both of the same periods in 2019. The increase in revenue is mainly due to further development of the third target nominated by GSK under the GSK Collaboration and License Agreement. Research and development RD expenses: RD expenses for the three and six months ended June 30, 2020 were 20.5 million and 41.7 million, respectively, compared to 25.5 million and 47.5 million for the same periods in 2019. The decreases in both periods are primarily due to lower development costs brought about by COVID-19 delays, a reduction in the average number of employees engaged in research and development, and in-process research and development costs of 2.0m in 2019 as a result of entering into a collaboration agreement with Alpine Immune Sciences, Inc. General and administrative GA expenses: GA expenses for the three and six months ended June 30, 2020 were 10.3 million and 19.6 million, respectively, compared to 10.1 million and 21.9 million for the same periods in 2019. The decrease in the six months ended June 30, 2020 was primarily driven by reduced travel costs and share-based compensation expense, partially offset by an increase in costs associated with commercialization. We expect that our general and administrative expenses will increase in the future as we expand our operations and move towards commercial launch. Other expense income, net: Other expense income, net for the three and six months ended June 30, 2020 was an expense of 0.7 million and income of 0.2 million, respectively, compared to expenses of 6.3 million and 0.8 million for the same periods in 2019. Other expense income, net primarily comprises unrealized foreign exchange movements, which fluctuate depending on exchange rates and the amount of foreign currency assets and liabilities. Net loss: Net loss attributable to holders of the Companys ordinary shares for the three and six months ended June 30, 2020 was 29.9 million and 58.0 million, respectively, and 0.04 and 0.07 per ordinary share, respectively, compared to 41.1 million and 68.5 million and 0.07 and 0.11 per ordinary share for the same periods in 2019. Financial guidanceThe Company believes that its existing cash, cash equivalents and marketable securities will fund the Companys current operations into 2022, as further detailed in the Companys Quarterly Report on Form 10-Q for the fiscal quarter ended June 30, 2020, to be filed with the Securities and Exchange Commission following this earnings release.Conference Call and Webcast Information The Company will host a live teleconference at 8:00 a.m. EDT 1:00 p.m. BST today, August 6, 2020. The live webcast of the conference call will be available in the investor section of Adaptimmunes corporate website at An archive will be available after the call at the same address. To participate in the live conference call, please dial 833 652-5917 U.S. or Canada or 1 430 775-1624 International. After placing the call, please ask to be joined into the Adaptimmune conference call and provide the confirmation code 5488705.About Adaptimmune Adaptimmune is a clinical-stage biopharmaceutical company focused on the development of novel cancer immunotherapy products for people with cancer. The Companys unique SPEAR Specific Peptide Enhanced Affinity Receptor T-cell platform enables the engineering of T-cells to target and destroy cancer across multiple solid tumors.Forward-Looking Statements This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 PSLRA. These forward-looking statements involve certain risks and uncertainties. Such risks and uncertainties could cause our actual results to differ materially from those indicated by such forward-looking statements, and include, without limitation: the success, cost and timing of our product development activities and clinical trials and our ability to successfully advance our TCR therapeutic candidates through the regulatory and commercialization processes. For a further description of the risks and uncertainties that could cause our actual results to differ materially from those expressed in these forward-looking statements, as well as risks relating to our business in general, we refer you to our Quarterly Report on Form 10-Q filed with the SEC on May 14, 2020, and our other SEC filings. The forward-looking statements contained in this press release speak only as of the date the statements were made and we do not undertake any obligation to update such forward-looking statements to reflect subsequent events or circumstances.Total Liquidity a non-GAAP financial measure Total Liquidity a non-GAAP financial measure is the total of cash and cash equivalents and marketable securities. Each of these components appears separately in the condensed consolidated balance sheet. The U.S. 